Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update

Core Viewpoint - Anavex Life Sciences Corp. is advancing its clinical-stage biopharmaceutical portfolio focused on innovative treatments for neurodegenerative diseases, particularly Alzheimer's disease and schizophrenia, with recent positive developments in clinical trials and financial results for Q2 fiscal 2025 [1][2]. Recent Highlights - The company successfully completed enrollment in its Phase 2 clinical study of ANAVEX®3-71 for schizophrenia, with a total of 71 participants [5]. - Anavex presented open-label-extension data for blarcamesine at the AD/PD™ 2025 conference, confirming its clinical benefits for early Alzheimer's patients [2]. - The appointment of Professor Dr. Audrey Gabelle to the Scientific Advisory Board enhances the company's expertise in Alzheimer's disease [5]. Financial Highlights - Cash and cash equivalents decreased to $115.8 million as of March 31, 2025, from $132.2 million at the end of fiscal 2024, indicating a runway of approximately 4 years at current utilization rates [5]. - General and administrative expenses for Q2 were $2.6 million, down from $2.9 million in the same quarter of fiscal 2024 [5]. - Research and development expenses increased slightly to $9.9 million compared to $9.7 million in the prior year [5]. - The net loss for Q2 was $11.2 million, or $0.13 per share, compared to a net loss of $10.5 million, or $0.13 per share, for the same quarter in fiscal 2024 [5][10].